News

  • 5 November 2019

    X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the initiation of a Phase 1b clinical trial of mavorixafor (X4P-001) for the treatment of Severe Congenital Neutropenia (SCN), a group of rare blood disorders characterized by abnormally low levels of neutrophils.

  • 4 November 2019

    X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the appointment of Derek Meisner, J.D., as General Counsel. Mr. Meisner brings more than two decades of experience providing counsel to public and private companies across key legal and operational functions, including regulatory compliance, debt and equity financings, mergers and acquisitions, strategic partnerships and corporate governance.

  • 24 October 2019

    Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announced today cash and cash equivalents of €3.1 million as of September 30, 2019. The existing cash and cash equivalents, including the French research tax credit for 2018 of €0.9 million received subsequent to the close of the third quarter, provide cash runway to end of Q1 2020. 

  • 7 October 2019

    Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing a novel implantable rechargeable sacral neuromodulation (“SNM”) system, today announced it achieved two milestones that expand its commercial reach in France and Norway. Specifically, the French Haute Autorité de Santé (“HAS”) published a positive recommendation required to gain reimbursement in France, and in Norway, a contract was awarded to supply the Axonics r-SNM® System to SNM-implanting hospitals in key cities.

  • 7 October 2019

    Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that the Company has filed a Premarket Notification 510(k) submission to  the U.S. Food and Drug Administration (FDA) for SNA-001, a topical pre-treatment to standard laser devices to remove unwanted light hair, and has received acknowledgement from FDA that the submission has been accepted.